A. Hillarp, K. Gustafsson, Lars Faxälv
Sep 1, 2014
Citations
5
Influential Citations
109
Citations
Quality indicators
Journal
Journal of Thrombosis and Haemostasis
Abstract
Apixaban is an oral direct factor Xa inhibitor developed for the prophylaxis and treatment of thromboembolic disorders. Laboratory monitoring is not necessary, but the effects on common coagulation reagents and assays constitute clinically valuable information.